HC Wainwright Forecasts Opus Genetics Q1 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for Opus Genetics in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.34) per share for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.24) EPS and FY2029 earnings at $0.00 EPS.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Monday, March 31st. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.93). Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. The business had revenue of $3.40 million during the quarter, compared to analyst estimates of $11.10 million.

Separately, Jones Trading cut their price objective on Opus Genetics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday.

Opus Genetics Stock Down 7.3 %

Shares of NASDAQ:IRD opened at $0.91 on Wednesday. The company has a market capitalization of $29.16 million, a PE ratio of -0.83 and a beta of 0.28. Opus Genetics has a 1-year low of $0.81 and a 1-year high of $1.56. The business’s 50 day simple moving average is $1.07.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.